<DOC>
	<DOCNO>NCT01552694</DOCNO>
	<brief_summary>People live human immunodeficiency virus infection ( HIV ) 2-4fold great risk develop diabetes heart disease general population . They need safe effective treatment reduce risk develop diabetes heart disease , improve quality life . This project explore whether new anti-diabetes medication ( Januvia ) novel mechanism action reduce inflammation , improve blood vessel function HIV infect men woman several risk factor develop cardiovascular disease .</brief_summary>
	<brief_title>Sitagliptin HIV</brief_title>
	<detailed_description>People live human immunodeficiency virus ( HIV+ ) infection 2-fold great prevalence incidence T2DM cardiovascular disease ( CVD ) general population . The investigator lack safe effective treatment HIV relate cardiometabolic complication despite fact HIV infect adult represent ideal clinical population study interaction among chronic low-grade pro-inflammatory process link development adipose accumulation , insulin resistance , ß-cell secretory failure , vascular endothelial dysfunction , atherosclerosis CVD . Dipeptidyl peptidase-IV ( DPP4 ) -inhibitors represent new drug class safely effectively regulate glycemia T2DM , adequately test HIV . Of note , pre-clinical study suggest DPP4-inhibitors several pleiotropic action may specifically benefit people live HIV infection . For example , DPP4 inhibition reduce adipose macrophage infiltration &amp; inflammation increase number bone-derived endothelial progenitor cell circulation . Our preliminary finding indicate DPP4 inhibition virologically immunologically safe non-diabetic HIV+ adult take combination antiretroviral therapy ( preparation ) , potential pleiotropic benefit examine HIV . The investigator propose randomize , double blind , placebo control physiological study test 2 potential pleiotropic benefit DPP4 inhibition ( 100 mg sitagliptin/d , 8 wk ) : reduce circulate adipose-specific marker inflammation ; increase endothelial progenitor cell number use vascular repair 36 HIV+ adult insulin resistance , central adiposity CVD risk factor . The investigator hypothesize sitagliptin reduce circulate cytokine level , reduce adipose tissue macrophage number inflammation , increase number circulate endothelial progenitor cell HIV infect men woman . These physiological study advance understanding efficacy DPP4 inhibition high-risk group , may help prevent inexorable transition insulin resistance T2DM CVD HIV infect men woman .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1865 yr old HIV infect men woman . Stable ( least past 6 month ) combine antiretroviral therapy ( cART ) . Stable immune ( &gt; 300 CD4+ Tcells/µL ) virologic ( &lt; 50 copy HIV RNA/mL ) status . Insulin resistant/impaired glucose tolerance ( fast glucose 100125mg/dL , 2hr glucose 140200mg/dL fast HOMAIR= 2.56.0 ) . Waist circumference &gt; 102 cm ( men ) , &gt; 88 cm ( woman ) . BMI &gt; 20 kg/m2 . Fasting hypertriglyceridemia &gt; 150 mg/dL . Low HDLcholesterol ( &lt; 40 mg/dL men &lt; 50 mg/dL woman ) . Platelet count &gt; 30,000/mm3 . Absolute neutrophil count &gt; 750/mm3 . Transaminases &lt; 2.5x upper limit normal . Longterm nonprogressors ( take antiHIV medication ) eligible . Diabetes ( T2DM , IDDM diabetic ketoacidosis ) take glucoselowering medication ( e.g. , insulin , TZDs , metformin , sulfonylurea ) . Any agent might artifactually alter glycemic control ( e.g. , glucocorticoid , megace , rhGH , GHsecretagogue , testosterone derivative , creatine monohydrate , chromium picolinate , AA/protein supplement , medium longchain fatty acid ) 6 month prior enrollment . History serious CV disease . NYHA Functional Class III IV ( e.g. , recent MI , unstable angina , edema , CHF , CAD , CABG , stroke , rest hypertension &gt; 160/95 mmHg ) , irregular heart rhythm , rest STsegment depression &gt; 1mm ) . Treatment medication CV condition ( e.g. , α ßblockers ) . Some BPlowering medication ( Ca++channel blocker , diuretic , ACE inhibitor ) permit . Moderate severe renal insufficiency . Serum creatinine &gt; 1.7 mg/dL ( men ) &gt; 1.5 mg/dL ( woman ) . Plan anticipate change antiHIV medication study . Lipidlowering medication permit ( fibrate statin niacin ) , must stable agent least 6 month prior enrollment . Lipidlowering agent start treatment period . Chronic hepatitis B ( HBVsurface antigen positive ) . Active hepatitis C ( detectable Hep C RNA ) . Positive urine drug test opiate , methamphetamine , heroin , cocaine . Active substance abuse MDscientist believe may compromise safety , compliance , interfere study drug data interpretation . Hematocrit &lt; 34 % men &lt; 25 % woman symptom ( fatigue , `` tiredlegs '' , shortness breath ) . Hemoglobin &lt; 10 gm/dL symptom . Pregnant nursing mother . Women must agree use acceptable form birth control study . If use birth control pillsmust stable medication least 6 month prior enrollment . Active malignancy treatment chemotherapeutic agent radiation therapy cytokine anticytokine therapy 6 month prior enrollment . History pancreatitis &gt; 10 % unintentional weight loss 6 month prior enrollment . Reduced cognitive function/unable provide voluntary inform consent . Prisoners exclude . Blinded investigational drug 3 month prior enrollment unblinded enrollment . Nausea , vomit , diarrhea ( &gt; 4 loose stools/day ) unresponsive treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>cardiometabolic complication</keyword>
</DOC>